Creative Planning Exact Sciences Corp Transaction History

Creative Planning

  • $101 Billion
  • Q3 2024

A detailed history of Creative Planning transactions in Exact Sciences Corp stock. As of the latest transaction made, Creative Planning holds 38,060 shares of EXAS stock, worth $2.21 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
38,060
Previous 33,154 14.8%
Holding current value
$2.21 Million
Previous $1.4 Million 85.07%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024
BUY
$42.43 - $70.83 $208,161 - $347,491
4,906 Added 14.8%
38,060 $2.59 Million
Q2 2024

Aug 15, 2024
BUY
$41.33 - $74.26 $204,748 - $367,884
4,954 Added 17.57%
33,154 $1.4 Million
Q1 2024

May 10, 2024
BUY
$56.27 - $73.77 $347,804 - $455,972
6,181 Added 28.07%
28,200 $1.95 Million
Q4 2023

Feb 14, 2024
BUY
$59.06 - $75.72 $139,440 - $178,774
2,361 Added 12.01%
22,019 $1.63 Million
Q3 2023

Nov 16, 2023
SELL
$65.94 - $99.04 $89,084 - $133,803
-1,351 Reduced 6.43%
19,658 $1.34 Million
Q2 2023

Jul 21, 2023
BUY
$62.68 - $95.05 $674,812 - $1.02 Million
10,766 Added 105.11%
21,009 $1.97 Million
Q1 2023

May 15, 2023
SELL
$47.19 - $70.77 $45,113 - $67,656
-956 Reduced 8.54%
10,243 $694,000
Q4 2022

Feb 10, 2023
SELL
$30.35 - $53.15 $526,390 - $921,833
-17,344 Reduced 60.76%
11,199 $554,000
Q3 2022

Nov 03, 2022
BUY
$31.97 - $49.37 $180,182 - $278,249
5,636 Added 24.6%
28,543 $927,000
Q2 2022

Aug 15, 2022
SELL
$35.61 - $76.23 $201,196 - $430,699
-5,650 Reduced 19.78%
22,907 $902,000
Q1 2022

May 16, 2022
BUY
$57.56 - $82.54 $385,536 - $552,852
6,698 Added 30.64%
28,557 $2 Million
Q4 2021

Feb 11, 2022
BUY
$72.5 - $100.68 $48,720 - $67,656
672 Added 3.17%
21,859 $1.7 Million
Q3 2021

Nov 10, 2021
BUY
$90.24 - $124.05 $1.39 Million - $1.91 Million
15,426 Added 267.77%
21,187 $2.02 Million
Q2 2021

Aug 04, 2021
SELL
$93.66 - $139.27 $360,591 - $536,189
-3,850 Reduced 40.06%
5,761 $716,000
Q1 2021

Apr 30, 2021
SELL
$116.57 - $155.01 $1.03 Million - $1.37 Million
-8,818 Reduced 47.85%
9,611 $1.27 Million
Q4 2020

Jan 29, 2021
SELL
$99.61 - $142.12 $1.76 Million - $2.51 Million
-17,634 Reduced 48.9%
18,429 $2.44 Million
Q3 2020

Nov 05, 2020
SELL
$72.92 - $102.01 $626,747 - $876,775
-8,595 Reduced 19.25%
36,063 $3.68 Million
Q2 2020

Jul 23, 2020
SELL
$55.75 - $92.75 $767,621 - $1.28 Million
-13,769 Reduced 23.57%
44,658 $3.88 Million
Q1 2020

May 05, 2020
SELL
$37.9 - $104.44 $294,558 - $811,707
-7,772 Reduced 11.74%
58,427 $3.39 Million
Q4 2019

Jan 30, 2020
SELL
$77.66 - $99.74 $1.1 Million - $1.41 Million
-14,168 Reduced 17.63%
66,199 $6.12 Million
Q3 2019

Nov 01, 2019
BUY
$90.37 - $122.49 $1.81 Million - $2.45 Million
19,976 Added 33.08%
80,367 $7.26 Million
Q2 2019

Jul 26, 2019
SELL
$89.51 - $118.04 $1.11 Million - $1.47 Million
-12,422 Reduced 17.06%
60,391 $7.13 Million
Q1 2019

Apr 24, 2019
BUY
$61.98 - $96.5 $386,817 - $602,256
6,241 Added 9.37%
72,813 $6.31 Million
Q4 2018

Feb 01, 2019
BUY
$56.04 - $82.66 $541,626 - $798,908
9,665 Added 16.98%
66,572 $4.2 Million
Q3 2018

Oct 25, 2018
SELL
$48.29 - $80.6 $471,310 - $786,656
-9,760 Reduced 14.64%
56,907 $4.49 Million
Q2 2018

Jul 20, 2018
SELL
$37.84 - $69.96 $263,555 - $487,271
-6,965 Reduced 9.46%
66,667 $3.99 Million
Q1 2018

Apr 18, 2018
BUY
$39.82 - $57.53 $809,381 - $1.17 Million
20,326 Added 38.13%
73,632 $2.97 Million
Q4 2017

Jan 17, 2018
SELL
$46.49 - $60.51 $188,842 - $245,791
-4,062 Reduced 7.08%
53,306 $2.8 Million
Q3 2017

Oct 17, 2017
BUY
$37.05 - $47.12 $2.13 Million - $2.7 Million
57,368
57,368 $2.7 Million

Others Institutions Holding EXAS

# of Institutions
673
Shares Held
162M
Call Options Held
2.58M
Put Options Held
2.19M
View Full List

About EXACT SCIENCES CORP

EXAS Quotes by TradingView
  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.3B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email